In clinical trial methodology as applied to therapeutic drug delivery, a non-inferiority trial evaluates whether an alternative formulation or route of administration (here, a subcutaneous fixed-dose co-formulation using a recombinant hyaluronidase-facilitated delivery mechanism) preserves efficacy and pharmacokinetic exposure comparable to an established intravenous formulation of a monoclonal antibody therapy, without requiring superiority. Non-inferiority is established via co-primary endpoints — a clinical efficacy measure (overall response rate) and a pharmacokinetic exposure measure (trough concentration at a specified treatment cycle) — assessed against a pre-specified non-inferiority margin using the lower bound of a confidence interval on the relative risk, alongside comparative evaluation of the safety and tolerability profile, including differences in administration-related and immunologic adverse events.
In clinical trial methodology as applied to therapeutic drug delivery, a non-inferiority trial evaluates whether an alternative formulation or route of administration (here, a subcutaneous fixed-dose…